Log in

NYSE:MD - MEDNAX Stock Price, Forecast & News

$27.38
-0.82 (-2.91 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$27.22
Now: $27.38
$28.15
50-Day Range
$22.29
MA: $25.57
$28.19
52-Week Range
$19.93
Now: $27.38
$38.88
Volume999,827 shs
Average Volume1.12 million shs
Market Capitalization$2.31 billion
P/E Ratio7.80
Dividend YieldN/A
Beta0.76
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services. Read More…

Industry, Sector and Symbol

Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
CUSIP58502B10
Phone954-384-0175

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 billion
Cash Flow$5.01 per share
Book Value$34.53 per share

Profitability

Net Income$268.62 million

Miscellaneous

Employees7,625
Market Cap$2.31 billion
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.


MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) issued its earnings results on Friday, November, 1st. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.08. The firm had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The company's quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the business posted $0.94 earnings per share. View MEDNAX's Earnings History.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX issued an update on its fourth quarter earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $0.87-0.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.93.

What price target have analysts set for MD?

9 brokers have issued 12 month price objectives for MEDNAX's stock. Their forecasts range from $18.00 to $36.00. On average, they anticipate MEDNAX's stock price to reach $27.67 in the next year. This suggests a possible upside of 1.0% from the stock's current price. View Analyst Price Targets for MEDNAX.

What is the consensus analysts' recommendation for MEDNAX?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Has MEDNAX been receiving favorable news coverage?

Media coverage about MD stock has trended positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEDNAX earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for MEDNAX.

Are investors shorting MEDNAX?

MEDNAX saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 7,700,000 shares, an increase of 14.8% from the November 14th total of 6,710,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is presently 6.6 days. Approximately 9.5% of the company's stock are sold short. View MEDNAX's Current Options Chain.

Who are some of MEDNAX's key competitors?

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Chevron (CVX), Dominion Energy (D), Walt Disney (DIS), Gilead Sciences (GILD), Intel (INTC), Kraft Heinz (KHC), AbbVie (ABBV), CVS Health (CVS), General Electric (GE) and UnitedHealth Group (UNH).

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:
  • Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 72)
  • Mr. Joseph M. Calabro, Pres (Age 58)
  • Mr. Stephen D. Farber, Exec. VP & CFO (Age 49)
  • Mr. David A. Clark, Chief Operating Officer (Age 52)
  • Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 50)

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.71%), First Trust Advisors LP (1.16%), Parametric Portfolio Associates LLC (0.56%), Man Group plc (0.51%), Millennium Management LLC (0.40%) and California Public Employees Retirement System (0.26%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

Which institutional investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, First Trust Advisors LP, Public Employees Retirement System of Ohio, Russell Investments Group Ltd., Wedge Capital Management L L P NC, Alberta Investment Management Corp and Squarepoint Ops LLC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

Which institutional investors are buying MEDNAX stock?

MD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Man Group plc, Assenagon Asset Management S.A., Parametric Portfolio Associates LLC, Mackay Shields LLC, State of New Jersey Common Pension Fund D, Voloridge Investment Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for MEDNAX.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $27.38.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $2.31 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

What is MEDNAX's official website?

The official website for MEDNAX is http://www.mednax.com/.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]


MarketBeat Community Rating for MEDNAX (NYSE MD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  465 (Vote Outperform)
Underperform Votes:  505 (Vote Underperform)
Total Votes:  970
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Featured Article: What is dividend yield?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel